Sun Pharma Q3 Results: PAT jumps 5.2% to Rs 2166 crore

The earnings before interest, tax, depreciation and ammortisation (EBITDA) grew 15.2% YoY to Rs. 3004 crore. The EBITDA margin for Q3FY23 improved 30 basis points YoY to 26.7%.Global specialty drug sales were at $235 million, including US$12.5 million milestone received in Q3FY23. Ex-milestone, the specialty sales were up 21.6% YoY in Q3FY23.

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.